[go: up one dir, main page]

AR092168A1 - Formulaciones parenterales de rasagilina - Google Patents

Formulaciones parenterales de rasagilina

Info

Publication number
AR092168A1
AR092168A1 ARP130102934A ARP130102934A AR092168A1 AR 092168 A1 AR092168 A1 AR 092168A1 AR P130102934 A ARP130102934 A AR P130102934A AR P130102934 A ARP130102934 A AR P130102934A AR 092168 A1 AR092168 A1 AR 092168A1
Authority
AR
Argentina
Prior art keywords
controlled release
subject
release formulation
rasagilina
pharmaceutically acceptable
Prior art date
Application number
ARP130102934A
Other languages
English (en)
Inventor
Fitzer-Attas Cheryl
E Eliaz Rom
Blaugrund Eran
Gross Aviva
Mayk Adi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR092168A1 publication Critical patent/AR092168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para inhibir de manera preferencial la monoamina oxidasa A (MAOA) en el cerebro de un sujeto, con relación a lo que podría observarse en el intestino del sujeto, que comprende administrarle por vía parenteral al sujeto una formulación de liberación controlada que comprende una cantidad eficaz para el uso terapéutico de rasagilina o de una sal farmacéuticamente aceptable de ésta. Reivindicación 26: Una formulación parenteral de liberación controlada caracterizada porque comprende rasagilina o una sal farmacéuticamente aceptable de ésta. Reivindicación 27: La formulación parenteral de liberación controlada de acuerdo con la Reivindicación 26, caracterizada porque está basada en una bomba osmótica.
ARP130102934A 2012-08-17 2013-08-16 Formulaciones parenterales de rasagilina AR092168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684530P 2012-08-17 2012-08-17
US201361775318P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
AR092168A1 true AR092168A1 (es) 2015-03-25

Family

ID=50100474

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102934A AR092168A1 (es) 2012-08-17 2013-08-16 Formulaciones parenterales de rasagilina

Country Status (10)

Country Link
US (1) US9308182B2 (es)
EP (1) EP2884972A4 (es)
JP (1) JP2015529196A (es)
AR (1) AR092168A1 (es)
BR (1) BR112015003451A2 (es)
CA (1) CA2882072A1 (es)
IL (1) IL237041A0 (es)
MX (1) MX2015002062A (es)
TW (1) TW201412304A (es)
WO (1) WO2014028868A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
WO2014141280A1 (en) * 2013-03-13 2014-09-18 Abital Pharma Pipelines Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO1998027055A1 (en) 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
ES2257051T3 (es) * 1998-05-27 2006-07-16 Avigen, Inc. Administracion potenciada por conveccion de vectores aav que codifican aadc.
US6670378B2 (en) * 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
CN101622225B (zh) 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
HUP0501084A2 (en) * 2005-11-23 2008-05-28 Richter Gedeon Nyrt New pharmaceutical compositions of high effectivity
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
KR101077835B1 (ko) 2006-12-14 2011-10-28 테바 파마슈티컬 인더스트리즈 리미티드 라사길린의 타닌산염
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
JP2011524353A (ja) 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
BRPI0909894A2 (pt) 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
WO2011042812A1 (en) 2009-10-09 2011-04-14 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
US20110152381A1 (en) 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
WO2012015950A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
KR20140074388A (ko) 2011-10-10 2014-06-17 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 시트라마이드
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан

Also Published As

Publication number Publication date
IL237041A0 (en) 2015-03-31
WO2014028868A1 (en) 2014-02-20
EP2884972A4 (en) 2016-05-11
JP2015529196A (ja) 2015-10-05
EP2884972A1 (en) 2015-06-24
CA2882072A1 (en) 2014-02-20
US9308182B2 (en) 2016-04-12
BR112015003451A2 (pt) 2017-07-04
US20140051767A1 (en) 2014-02-20
TW201412304A (zh) 2014-04-01
MX2015002062A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
BR112013003772A2 (pt) composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
CL2009000533A1 (es) Uso de una variante de defensina parenteral contra la tuberculosis; que comprende una sustitucion d9s en el polipeptido maduro; metodo para eliminar o inhibir mycobacterium in vitro.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
MX2013005292A (es) Sal (es) de dimetil-amida del acido 7-ciclopentil-2- (5-piperazin-1-il-piridin-2-il-amino) -7h-pirrolo- [2, 3-d]-pirimidin-6-carboxilico y procesos para su elaboracion.
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
AR093705A1 (es) Depsipeptido y sus usos
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
AR092168A1 (es) Formulaciones parenterales de rasagilina
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CL2015002047A1 (es) Uso de sales de tungsteno (vi) para el tratamiento de la infertilidad femenina en mamíferos no diabeticos
CO7121334A2 (es) Formulaciones vesiculares
ECSP15033898A (es) Composición antifúngica tópica para el tratamiento de onicomicosis
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112015013106A2 (pt) uso de extrato de feno-grego para melhorar a libido feminina
MX2017009514A (es) Moduladores de los receptores a3 de adenosina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure